Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumor, Adult × atezolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 51 Carcinoma, Hepatocellular 27 Breast Neoplasms 24 Small Cell Lung Carcinoma 18 Triple Negative Breast Neoplasms 17 Lung Neoplasms 16 Urinary Bladder Neoplasms 14 Neoplasms 14 Neoplasm Metastasis 14 Melanoma 14 Carcinoma, Transitional Cell 14 Colorectal Neoplasms 13 Uterine Cervical Neoplasms 9 Head and Neck Neoplasms 7 Carcinoma, Renal Cell 7 Stomach Neoplasms 6 Recurrence 6 Prostatic Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Sarcoma 5 Mesothelioma, Malignant 5 Liver Neoplasms 5 Carcinoma, Squamous Cell 5 Ovarian Neoplasms 4 Carcinoma, Merkel Cell 4 Thoracic Neoplasms 3 Solid Tumors 3 Rectal Neoplasms 3 Lymphoma, Follicular 3 Lymphoma 3

Interventions

tislelizumab 1 pembrolizumab 1 patritumab deruxtecan 1 leronlimab 1 lenvatinib 1 atezolizumab 1 Tiragolumab 1 Radiotherapy 1 Cryosurgery 1 3-amino-1-methyl-3-(4-(3-phenyl-5H- imidazo(1,2-c)pyrido(3,4-e)(1,3)oxazin-2-yl)phenyl)cyclobutanol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06003621 2024-11-15

MoST-TAP

Omico

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon ⚡